GC
The startup develops immune cell-based therapeutics utilizing a platform for screening and optimizing ancillary proteins to enhance target immune cell responses against cancer and inflammatory disorders. Additionally, it creates multi-valent sub-unit vaccines for COVID-19, leveraging expertise in protein engineering and immunology to improve treatment efficacy.
성남시, 대한민국
Updated 2 months ago
Funding
$89.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops immune cell-based therapeutics utilizing a platform for screening and optimizing ancillary proteins to enhance target immune cell responses against cancer and inflammatory disorders. Additionally, it creates multi-valent sub-unit vaccines for COVID-19, leveraging expertise in protein engineering and immunology to improve treatment efficacy.